Illinois Medicaid and GLP-1 coverage

The Illinois rule excludes these drugs from the pharmacy benefit. Under "Pharmacy Services Not Covered" it says "Items excluded from coverage include the following:" and the second entry is "Anorectic drugs or combinations including such drugs."

89 Ill. Adm. Code 140.441, Illinois General Assembly Joint Committee on Administrative Rules, effective May 2014 · source

The state's pharmacy handbook says it without the terminology. Under the heading "Prescription pharmacy items that are not covered under the Medical Assistance Program are:" one of the bullets reads "Weight loss drugs."

Illinois Department of Healthcare and Family Services, Handbook for Providers of Pharmacy Services, Chapter P-200, effective March 2016 · source

The state's criteria for this drug class name the products. They sort these medicines into groups, and the last group is headed "Not covered agents:" — under it sit Saxenda, Wegovy injection, Wegovy tablets and Zepbound. The same document lists, among the reasons a request is refused, that the "Medication requested is used either for obesity alone or in combination with another condition secondary to obesity (IL Medicaid policy)," and every approval pathway in it requires a type 2 diabetes diagnosis. ⚠ Two notes on this document: it is published on the prior-authorization site the state links from its own criteria page rather than on a state domain, and it prints an effective date of April 2025 while citing prescribing information dated 2026, so it has been revised since the date it shows.

Illinois Department of Healthcare and Family Services, Formal Criteria for the Illinois Medicaid Fee-For-Service Program, effective April 2025 · source · criteria document

None of these drugs is on the Illinois drug list. Across its 5,804 rows there is no anti-obesity or anorectic class heading, and no Wegovy, Zepbound, Saxenda, Contrave, Qsymia, Xenical, orlistat or phentermine. Ozempic and Trulicity are there, under "ANTIDIABETICS : INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)," so they are absent from the list rather than from our reading of it. In that class Trulicity, Victoza and liraglutide are preferred, Ozempic tablets and Rybelsus preferred with prior authorization, and Ozempic injection, Mounjaro, Byetta and exenatide non-preferred.

Illinois Department of Healthcare and Family Services, Illinois Medicaid Preferred Drug List, effective July 2026 · source

If a HealthChoice Illinois plan denies you, the plan's own appeal comes first: "You may appeal within sixty (60) calendar days of the date on the Notice of Adverse Benefit Determination letter that you receive from your health plan." Then the state hearing, with a second date buried in the same sentence that decides whether your medicine continues: "you may ask for a State Fair Hearing within one hundred and twenty (120) calendar days of the date on the Notice of Appeal Resolution from your health plan, but you must ask for a State Fair Hearing within ten (10) calendar days of the date on the Notice of Appeal Resolution if you want to continue your services." ⚠ This document carries no date on its face and still lists a plan that no longer operates here, so treat the numbers as what Illinois publishes and confirm them against your own notice.

Illinois Department of Healthcare and Family Services, Bureau of Administrative Hearings · source

On whether the plans must follow the state list, here is the strongest current sentence we found, and it is narrower than a general rule. A May 2026 provider notice about GLP-1 drugs says "This change will apply to both the fee-for-service (FFS) program and Managed Care Organizations (MCOs) plans." That is a statement about that change. We looked for a standing requirement in the pharmacy rule, the state statute and the program's own pages and did not find one, so check your own plan's drug list rather than assuming.

Illinois Department of Healthcare and Family Services, Provider Notice, effective May 2026 · source